Connect with us

Science

3 Alzheimer’s Disease Treatment Stocks on the NASDAQ

The Alzheimer’s disease treatment market is projected to reach US$9.4 billion by 2027. Which stocks should be on investors’ radar?
The post 3 Alzheimer’s Disease Treatment Stocks on the NASDAQ appeared first on Investing News Network.

Published

on

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills. 

According to the  Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.

This condition affects more than 6.2 million people in the US alone; it’s also the most common form of dementia and is the sixth leading cause of death in America.

 

Coronavirus:An Overview for Investors

 
COVID-19 continues to impact world markets. Get INN’s overview of coronavirus investing.
 

Treatments are available to alleviate Alzheimer’s symptoms, but because they do not affect the underlying causes of the neurodegenerative disease, they’re only a bandaid solution.

Therapies approved by the US Food and Drug Administration include: rivastigmine by Novartis (NYSE:NVS); galantamine, developed by Janssen, a division of Johnson & Johnson (NYSE:JNJ); donepezil by Pfizer (NYSE:PFE); and memantine, now under AbbVie (NYSE:ABBV).

Although these and other treatments are available, there is no cure for Alzheimer’s, and death is often the result for patients as the disease devastates the brain.

And, unfortunately, Alzheimer’s disease is rising in prevalence. A report from Research and Markets suggests the global Alzheimer’s market will be worth US$9.4 billion by 2027 thanks to the rising need for drugs in development, along with investments made in biomarkers for further development.

Here the Investing News Network takes a look at a few of the biggest Alzheimer’s disease treatment stocks. Companies are listed in order of market cap from largest to smallest. All data for the Alzheimer’s disease treatment stocks on this list was current as of September 7, 2021.

1. Prothena (NASDAQ:PRTA)

Market cap: US$3.24 billion; current share price: US$71.89

The first Alzheimer’s disease treatment stock on this list is Prothena. This late-stage clinical company has developed a pipeline of novel therapeutics for the treatment of a number of neurodegenerative diseases, including Alzheimer’s disease, AL amyloidosis, ATTR amyloidosis and Parkinson’s disease.

In mid-2021, Prothena presented new data from its ongoing clinical studies of PRX005 for the treatment of Alzheimer’s disease. The company also received US$80 million from Bristol Myers Squibb (NYSE:BMY) for the exclusive US license to PRX005, with the option for worldwide rights following completion of an already initiated Phase 1 study. An investigational new drug application for PRX012 is expected to be filed by the company in the first quarter of 2022.

2. AC Immune (NASDAQ:ACIU)

Market cap: US$528.91 million; current share price: US$7.28

AC Immune’s overall focus is on developing treatments for neurodegenerative diseases such as Alzheimer’s. The company has two proprietary technology platforms: SupraAntigen and Morphomer. Within these platforms are eight Alzheimer’s disease treatments in different stages of clinical trials.

AC Immune’s lead Alzheimer’s drug candidate is crenezumab, an anti-Abeta antibody that is currently in a Phase 2 clinical trial for Alzheimer’s. The company recently released positive top-line data for another of its Alzheimer’s product candidates, semorinemab, which is also in Phase 2 studies.

3. Adamas Pharmaceuticals (NASDAQ:ADMS)

Market cap: US$209.28 million; current share price: US$4.59

Adamas Pharmaceuticals is focused on neurological conditions in patients with Parkinson’s disease, multiple sclerosis, epilepsy and Alzheimer’s.

The company’s Alzheimer’s dementia treatment, Namzaric, was developed in connection with Allergan and approved by the US Food and Drug Administration in 2014; Allergan was acquired by AbbVie in early 2020. Namzaric is a treatment taken once daily to treat moderate to severe Alzheimer’s and helps improve symptoms such as cognition and function impairment.

This is an updated version of an article first published by the Investing News Network in 2019. 

Don’t forget to follow @INN_LifeScience for real-time updates!

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

The post 3 Alzheimer’s Disease Treatment Stocks on the NASDAQ appeared first on Investing News Network.

Read More

Continue Reading

Spread & Containment

Huge Dock Worker Protests In Italy, Fears Of Disruption, As Covid ‘Green Pass’ Takes Effect

Huge Dock Worker Protests In Italy, Fears Of Disruption, As Covid ‘Green Pass’ Takes Effect

Following Israel across the Mediterranean being the first country in the world to implement an internal Covid passport allowing only vaccinated citize

Published

on

Huge Dock Worker Protests In Italy, Fears Of Disruption, As Covid 'Green Pass' Takes Effect

Following Israel across the Mediterranean being the first country in the world to implement an internal Covid passport allowing only vaccinated citizens to engage in all public activity, Italy on Friday implemented its own 'Green Pass' in the strictest and first such move for Europe

The fully mandatory for every Italian citizen health pass "allows" entry into work spaces or activities like going to restaurants and bars, based on one of the following three conditions that must be met: 

  • proof of at least one dose of Covid-19 vaccine

  • or proof of recent recovery from an infection

  • or a negative test within the past 48 hours

Via AFP

It's already being recognized in multiple media reports as among "the world's strictest anti-COVID measures" for workers. First approved by Italian Prime Minister Mario Draghi's cabinet a month ago, it has now become mandatory on Oct.15.

Protests have been quick to pop up across various parts of the country, particularly as workers who don't comply can be fined 1,500 euros ($1,760); and alternately workers can be forced to take unpaid leave for refusing the jab. CNN notes that it triggered "protests at key ports and fears of disruption" on Friday, detailing further:

The largest demonstrations were at the major northeastern port of Trieste, where labor groups had threatened to block operations and around 6,000 protesters, some chanting and carrying flares, gathered outside the gates.

    Around 40% of Trieste's port workers are not vaccinated, said Stefano Puzzer, a local trade union official, a far higher proportion than in the general Italian population.

    Workers at the large port of Trieste have effectively blocked access to the key transport hub...

    As The Hill notes, anyone wishing to travel to Italy anytime soon will have to obtain the green pass: "The pass is already required in Italy for both tourists and nationals to enter museums, theatres, gyms and indoor restaurants, as well as to board trains, buses and domestic flights."

    The prime minister had earlier promoted the pass as a way to ensure no more lockdowns in already hard hit Italy, which has had an estimated 130,000 Covid-related deaths since the start of the pandemic.

    Meanwhile, the requirement of what's essentially a domestic Covid passport is practically catching on in other parts of Europe as well, with it already being required to enter certain hospitality settings in German and Greece, for example. Some towns in Germany have reportedly begun requiring vaccination proof just to enter stores. So likely the Italy model will soon be enacted in Western Europe as well.

    Tyler Durden Sat, 10/16/2021 - 07:35

    Read More

    Continue Reading

    Government

    4 In 10 TSA Employees Remain Unvaccinated As Deadline Looms

    4 In 10 TSA Employees Remain Unvaccinated As Deadline Looms

    While we wait to see what remains of the US army after hundreds of thousands of unvaccinated troops are told to pack up for not complying with Biden’s executive order (and whether…

    Published

    on

    4 In 10 TSA Employees Remain Unvaccinated As Deadline Looms

    While we wait to see what remains of the US army after hundreds of thousands of unvaccinated troops are told to pack up for not complying with Biden's executive order (and whether that's the moment China will decided to attack), we wonder if soon nobody will be able to fly as a few weeks from now the Transportation Security Administration may simply cease to exist.

    According to CNN, the TSA says 4-in-10 members of its workforce, including screeners, remain unvaccinated against Covid-19 just weeks ahead of a looming deadline. The deadline for civilian federal government workers to be fully vaccinated is November 22 - the Monday before Thanksgiving, which just happens to be the busiest travel time of the year.

    "We have about 60% of our workforce has been vaccinated, that that number needs to go quite a bit higher over the next few weeks," TSA Administrator David Pekoske told CNN.

    The November 22 deadline for being fully vaccinated is still six weeks away, but the deadlines for receiving the vaccines are rapidly approaching or, in the case of the Moderna vaccine, have already passed, since an individual has to receive the full schedule of doses and wait two weeks before being considered fully vaccinated.

    In order to meet that deadline, the last possible date for receiving the first dose of the Pfizer vaccine is October 18, while the latest possible date for the first dose of Moderna was October 11. According to CNN, the Pfizer vaccine requires a three-week waiting period in between first and second doses. Moderna requires a four-week wait. The last possible date to receive the single-dose Johnson & Johnson vaccine is November 8, two weeks before the November 22 deadline.

    Pekoske said he is "very hopeful" that the agency's employees can meet the deadline and that there will not be worker shortages, however in light of mandatory requirements that clearly will not happen.

    "We are building contingency plans, for if we do have some staffing shortages as a result of this, but I hope to avoid that," he said.

    It wasn't clear what, if any, these contingency plans are.

    Tyler Durden Fri, 10/15/2021 - 18:50

    Read More

    Continue Reading

    Government

    “Expert” Calls For Denying Life-Saving Hospital Treatment To The Unvaccinated

    "Expert" Calls For Denying Life-Saving Hospital Treatment To The Unvaccinated

    Authored by Paul Joseph Watson via Summit News,

    An “expert” whose work on cybersecurity has been cited by the NY Times and the Washington Post announced on…

    Published

    on

    "Expert" Calls For Denying Life-Saving Hospital Treatment To The Unvaccinated

    Authored by Paul Joseph Watson via Summit News,

    An “expert” whose work on cybersecurity has been cited by the NY Times and the Washington Post announced on Twitter that the unvaccinated should be denied life-saving hospital treatment because they are “not fit for life on earth.”

    Chris Vickery, who describes himself as a “data breach hunter” also brags about how his “findings have contributed to investigations conducted by the FTC, FBI, SEC, Secret Service, HHS, SSCI, and more.”

    During an unhinged Twitter rant, Vickery asserted that a time limit of December 1st should be put on people refusing to take the COVID-19 vaccine.

    “Set a date now. After that date, no hospital services for the willingly unvaccinated,” he screeched.

    “Then, after the chosen date, anyone choosing to refuse the covid-19 vaccine can deal with the consequences of that choice alone,” added Vickery.

    After claiming there was no “legitimate” reason for anyone to refuse the shot, Vickery ended his rant with a demented call for such people to “separate from the surviving world.”

    “Human society isn’t a suicide pact. If you are too dumb to get the covid vaccine, then you are not fit for continued life on Earth.”

    “That’s your choice, but the consequences of refusing to get the vaccine is you having to wave a fond farewell and separate from the surviving world.”

    Some joked that this was yet another example of the familiar trend of blue checkmarks on Twitter aggressively displaying their virtue while actually calling for mass genocide.

    Others directly savaged Vickery for his heartless inhumanity.

    “When you were a child, did you ever envisage what a terrible person you would be in adulthood?” asked one.

    “So much for “healthcare is a human right,” quipped another.

    Vickery later bragged about the number of people he had blocked on Twitter in the aftermath of his comments.

    How brave of him.

    As we previously highlighted, numerous hospitals across America are already denying life-saving organ transplants to unvaccinated patients.

    Meanwhile, in the UK, patients deemed to be “racist,” “sexist” or “homophobic” can also be denied treatment under NHS rules.

    As we document in the video below, similar rhetoric is being spewed by Keith Olbermann and others who are intent on whipping up ‘New Normal’ cult members into a frenzied, hysterical hatefest targeting those who choose not to take the jab.

    *  *  *

    Brand new merch now available! Get it at https://www.pjwshop.com/

    In the age of mass Silicon Valley censorship It is crucial that we stay in touch. I need you to sign up for my free newsletter here. Support my sponsor – Turbo Force – a supercharged boost of clean energy without the comedown. Get early access, exclusive content and behinds the scenes stuff by following me on Locals.

    Tyler Durden Fri, 10/15/2021 - 15:43

    Read More

    Continue Reading

    Trending